© CEOCFO Magazine -
CEOCFO Magazine, PO Box 340
Palm Harbor, FL 34682-
Business Services | Solutions
Medical | Biotech
Cannabis | Hemp
Banking | FinTech | Capital
Industrial | Resources
Global | Canadian
Lynn Fosse, Senior Editor
Steve Alexander, Associate Editor
Bud Wayne, Marketing
& Production Manager
Christy Rivers -
Etiometry Enhances Clinical Decision Support Platform
President & CEO
Interview conducted by:
Lynn Fosse, Senior Editor
Published – December 21, 2020
CEOCFO: Mr. Cooke, it has been about a year since we have spoken about Etiometry. How has the company changed over the last year?
Mr. Cooke: The market and the company have changed substantially in 2020. The pandemic has impacted us all and has certainly had a major impact on the healthcare community. Even with all the changes that have taken place in the market, we have made great progress this year as a company by enhancing our platform, generating clinical evidence, and growing our footprint. I am proud of the Etiometry team for what we have been able to accomplish, and most importantly for the hospitals and the patients that we have been able to help during this time.
CEOCFO: According to your website, Etiometry is transforming critical care data into clinical insights. How are you doing so?
Mr. Cooke: Our end-
We are a web-
Our core focus as a company is developing patient risk algorithms driven by our unique model-
Our platform also includes a clinical database that enables researchers and quality improvement professionals to easily access high-
CEOCFO: What does the FDA look at to give you the stamp of approval for this type of solution?
Mr. Cooke: We submit a tremendous amount of data to the FDA with all our submissions which show correlations between our algorithms and invasive monitoring parameters and laboratory results, as well as performance data for our algorithm.
For instance, our inadequate delivery of oxygen index (IDO2) continuously assesses the likelihood that if a clinician were to draw a mixed venous oxygenation, or SvO2, it would be below 40%. The correlation and statistical data we submit to the FDA shows our ability to assess this likelihood consistently and accurately.
CEOCFO: How are you able to gain attention from hospitals that are scrambling around just to exist day-
Mr. Cooke: It has certainly been a challenging year for hospitals, and especially ICUs, with the increased patient load. Our goal is to help them as much as we can, and our remote monitoring capabilities were highly sought throughout this year. We have expanded our bed coverage at most of our partner hospitals this year, mostly for free, to ensure they had advanced monitoring coverage throughout their critical care units. Expansions into pediatric ICUs, neonatal ICU and adult ICUs was a major focus for our company this year, and we have also signed several new customers who see the benefit of remote monitoring, and the clinical insights we provide with our risk algorithms.
CEOCFO: Are you continually adding to what information you can incorporate or are there only so many things that can be measured?
Mr. Cooke: We are continually adding more information into our platform and algorithms, and this comes from partnering with our customers and key clinicians. In late November, we received our sixth FDA clearance for the platform, which shows our ability to rapidly iterate to meet customer needs. This latest FDA clearance includes new features which enhance the use of our risk algorithms, helping to answer why an algorithm may be elevated. This clearance also enhances the access & visualization of our platform with our Surveillance View, which shows key parameters and trends for all patients within a unit.
Some of the other enhancements that we have added this year include incorporating new data elements into our algorithms as well as getting more access to information from the electronic medical records such as vasoactive medications that can be viewed in our platform. We are focused on adding as much information as possible, to help clinicians make more informed decisions for their patients.
CEOCFO: Do you find most clinicians know what they should be reviewing?
Mr. Cooke: The doctors, nurses, and respiratory therapists we regularly interact with are fantastic and they know what they are looking at and looking for. One of the key challenges, especially in the critical care environment, is that there is so much data to process, from several different sources, and quick decisions need to be made for the challenging patient conditions that are a mainstay in the ICU, ED and OR. The pandemic has added more complexity to the situation, with the influx of patients, and the need for PPE and sanitizing which is a further draw on clinicians’ time. Harnessing information into one platform and providing additional clinical insights with our algorithms is helpful to cut down on the data overload which is often present.
I have read some stories this year about the level of burnout for clinicians during this pandemic. Burnout in the ICU has always been an issue and it has been exacerbated by the pandemic, and while they already know what they are looking for, being able to provide an efficient way to get that information is always helpful.
CEOCFO: As medical research changes, how does that information get incorporated in your software solutions? How do you keep up with what might make a difference?
Mr. Cooke: Our approach to analytics separates us from any other data and analytics company in the market. We have a physiology model-
Our model is based on the core fundamentals of physiology and looking at the primary physiological risks within a patient. That does not change over time but what does change is the new information we can incorporate to further enhance our ability to assess the risk of the patients and their risk of being in an adverse physiological state. As far as research goes, our product is very helpful with clinical research because we automatically collect and store patient data and the hospital can use the data to drive their own research and quality initiatives. We have had several abstracts from clinical studies accepted for presentation this year which used our software to collect the data.
CEOCFO: How did you decide this model is the way to go? Why have other solutions not relied on the power of physiology?
Mr. Cooke: I think others recognize the power of physiology, however one thing that makes us different is where the company started. The company co-
In short, our model-
CEOCFO: Might this be useful eventually for most patients or all patients?
Mr. Cooke: Our vision is to be the global leader in clinical decision support, throughout the continuum of care. While we have primarily focused our efforts on the ICU, and early on in cardiac ICUs, this year we have expanded into new markets, such as pediatric ICUs, neonatal ICUs, and adult ICUs.
We have also expanded into other new departments such as the operating room, post-
CEOCFO: If you start with a new hospital today, might they look to use the Etiometry platform in several different areas or is it typically starting in one and then adding on over time?
Mr. Cooke: If you went back one or two years, we would most likely be starting in one unit, and over time, may move to other units as well. However, right now hospitals are typically starting with a couple units and we expect them to increase beyond that over time. This is a function of the markets we have recently entered, the clinical workflows we are supporting in these new units, and the clinical evidence we are driving. As we progress over the next twelve to eighteen months you will start to see that a new hospital that comes onboard is starting in three or four or more units, especially as they see the benefit of visualizing longitudinal data as patients may move from the emergency department to the OR to the ICU.
CEOCFO: How are you reaching out to new customers?
Mr. Cooke: The awareness of our platform is growing and the ICUs we focus on have very tight-
Being in a remote commercial mode throughout most of this year was challenging, however, we leverage our key contacts at hospitals to get introduced to other ICUs and departments, and this has been a major driver of our expansion in 2020.
I am hopeful that with the vaccine and continued focus on distancing and other safety measures, we can all return to some sense of normalcy next year. I miss being in the ICUs and having face-
CEOCFO: What is ahead for Etiometry for 2021?
Mr. Cooke: We are very excited about the key objectives we are driving towards in 2021. We are focused on continuing to grow our customer base; we doubled our customer base this year and we are looking to do that again in 2021, continuing to expand into new markets with larger patient populations.
We have several ongoing clinical studies that will hopefully be in publication next year, and we will continue to advance the technology platform, with new features and new risk algorithms. We are the only company with two FDA-
CEOCFO: Final thoughts?
Mr. Cooke: I am very proud of the Etiometry team for all the progress we have made, especially considering what is going on in the market. Stay safe and healthy!
Etiometry Inc., Shane Cooke, ICU Predictive Analytics, Intensive Care Unit Information Technology, Etiometry Enhances Clinical Decision Support Platform, CEO Interviews 2020, Medical Companies, ICU clinical data, Critical Care Patient Data, The Etiometry Platform Enables More Informed Decision Making, Clinical Insights, critical care data, clinical decision support software, intensive care software solutions, healthcare data analytics, medical date analytics, critical care data analytics, data management software, hemodynamic data analytics, respiratory data analytics, Etiometry Inc. Press Release, News, Blog